HK Stock Market Move | INNOVENT BIO (01801) increased by nearly 5% and will officially turn blue starting on December 8th.

INNOVENT BIO (01801) rose nearly 5% at one point, as of the time of writing, it has risen by 3.9% to 90.65 Hong Kong dollars, with a turnover of 177 million Hong Kong dollars. On the news front, on November 21, the results of the quarterly review of the Hang Seng Index series were released, and all changes will take effect from December 8, 2025. Among them, INNOVENT BIO will be included in the Hang Seng Index constituents, increasing the number of constituents from 88 to 89. It is worth noting that on November 20, INNOVENT BIO announced that the Maradulitin injection (Glucagon-like peptide-1 [GLP-1] dual receptor agonist, research code: IBI362) in the Phase III clinical trial (GLORY-2) conducted in Chinese middle-aged and obese populations reached primary endpoints and all key secondary endpoints. INNOVENT BIO will soon submit a new drug application for Maradulitin 9mg for adult weight control.